Brokerage Firm Rating Update on Pfizer (PFE)

Pfizer (PFE) has an average broker rating of 1.92, which is interpreted as a Buy, as rated by 13 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Pfizer (PFE) : Currently there are 12 street experts covering Pfizer (PFE) stock. The most bullish and bearish price target for the stock is $54 and $33 respectively for the short term. The average price target of all the analysts comes to $39.58. The estimated standard deviation from the target is $5.62.


For the current week, the company shares have a recommendation consensus of Buy. Also, In a research note released to the investors, Jefferies maintains its rating on Pfizer (NYSE:PFE).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Jefferies lowers the new price target from $41.5 per share to $40 per share. The rating by the firm was issued on August 4, 2016.

Pfizer (NYSE:PFE): The stock opened at $34.72 and touched an intraday high of $34.89 on Wednesday. During the day, the stock corrected to an intraday low of $34.68, however, the bulls stepped in and pushed the price higher to close in the green at $34.84 with a gain of 0.20% for the day. The total traded volume for the day was 14,815,540. The stock had closed at $34.77 in the previous trading session.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.